Document text
Principal Investigator: Richard J. Kuhn
Organization: PURDUE UNIVERSITY
Fiscal Year: 2021
Award: $30,170
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
This proposal aims to rapidly generate vaccine candidates against the 2019 novel coronavirus SARS-CoV-
2. Since its emergence about three months ago, this virus has caused more than 120,000 infections and 4,300
deaths worldwide and is rapidly spreading to virtually every country including the United States. This global
health emergency must be immediately addressed by rapidly developing medial countermeasures.
Our bacteriophage (phage) T4 vaccine platform is uniquely suited to address this threat. Developed in PI's
laboratory, the T4 vaccines have been proven to generate robust humoral as well as cellular immune responses
and confer complete protection against anthrax and plague in multiple animal models including mice, rats,
rabbits, and macaques. The T4 vaccines do not need an adjuvant as its surface structure mimics the Pathogen-
Associated Molecular Patterns (PAMPs) of viral pathogens and stimulate strong innate and adaptive immunity.
The 120 x 86 nm phage T4 capsid is packaged with 171 kb genome and decorated with two non-essential
outer capsid proteins; 870 molecules of Soc (small outer capsid protein) and 155 copies of Hoc (highly antigenic
outer capsid protein). In specific aim 1, a series of T4-corona phages will be constructed by incorporating SARS-
CoV-2 virion components individually and in combinations, by CRISPR engineering. The gene encoding the
entire spike ectodomain will be inserted into phage genome under the control of the strong CAG promoter. Upon
immunization, host cells (myocytes and antigen presenting cells at the site of immunization) take up phage
particles and secrete the ectodomain trimers continuously, stimulating the immune system for weeks to months.
The gene for the receptor binding domain (RBD) of S protein will be inserted such that the RBD will be expressed
in host cells, as well as in E. coli as a Soc fusion protein which will then be displayed on phage capsid up to 870
copies per capsid. The ectodomain of E protein will be fused to Hoc and displayed up to 155 copies per capsid.
Finally, ~400 copies of N protein will be packaged inside the capsid as part of the scaffolding core.
In specific aim 2, the above T4-corona recombinant phages will be evaluated for elicitation of SARS-CoV-
2 virion-specific immune responses in a mouse model. Mice will be immunized with purified phage particles
intramuscularly and the immune responses will be quantified by ELISA, competitive receptor binding, ELISpot,
and virus neutralization assays. We expect that the T4-corona vaccines will elicit robust antibody and cellular
responses and also inform which candidate(s) will be most effective in blocking SARS-CoV-2 infection.
We have streamlined the CRISPR engineering such that the proposed T4 vaccines can be constructed in
about 4 weeks and the animal testing can be completed in about 12 weeks. The candidate vaccines will then be
available for clinical trials and vaccine manufacture. The T4 vaccine will be exceedingly easy to manufacture,
scale, and distribute globally, and could potentially lead to a breakthrough to avert the coronavirus crisis.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Address><Adjuvant><Americas><Animal Model><Animal Models and Related Studies><Animal Testing><Anthrax><Anthrax disease><Antibodies><Antigen-Presenting Cells><Antigens><Antisera><Assay><Bacteriophage T4><Bacteriophages><Basic Research><Basic Science><Bioassay><Biologic Assays><Biological Assay><COVID-19 infection><COVID-19 vaccine><COVID-19 virus><COVID19 infection><COVID19 vaccine><COVID19 virus><CRISPR><CRISPR-nanoparticles><CRISPR/Cas system><Capsid><Capsid Proteins><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cell Body><Cells><Cessation of life><Chimera Protein><Chimeric Proteins><China><Cities><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats nanoparticles><CoV emergence><CoV-2><CoV2><Coat Proteins><Coliphage T4><Common Rat Strains><Coronaviridae><Coronavirus><Country><Death><Domestic Rabbit><E coli><E protein><E. coli><ELISA><Engineering><Enterobacteria phage T4><Envelope Protein><Enzyme-Linked Immunosorbent Assay><Escherichia coli><Fusion Protein><Future><Generations><Genes><Genome><Goals><Heart Vascular><Human><Immune Sera><Immune response><Immune system><Immunization><Immunize><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Individual><Infection><Innate Immunity><Intramuscular><Laboratories><Lead><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Macaca><Macaque><Mainland China><Medial><Mice><Mice Mammals><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular><Murine><Mus><Muscle Cells><Myocytes><Native Immunity><Natural Immunity><Non-Specific Immunity><Nonspecific Immunity><Nucleocapsid Proteins><Oryctolagus cuniculus><Pattern><Pb element><Phages><Plague><Population><Protein Binding Domain><Protein Binding Motif><Protein-Protein Interaction Domain><Proteins><Province><Rabbits><Rabbits Mammals><Rat><Rats Mammals><Rattus><Receptor Gene><Recombinants><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-CoV2 vaccine><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Structure><Surface><T4 Phage><TLR protein><Technology><Testing><Time><Toll-Like Receptor Family Gene><Toll-like receptors><Translational Research><Translational Science><United States><Vaccines><Viral Coat Proteins><Viral Outer Coat Protein><Virion><Virus><Virus Particle><Wuhan coronavirus><Yersinia pestis disease><accessory cell><adaptive immunity><allergic/immunologic body system><allergic/immunologic organ system><bacterial virus><bio-threat><biodefense><biothreat><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><circulatory system><corona virus><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019 infection><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus emergence><coronavirus vaccine><deliver vaccines><design><designing><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><env Antigens><env Gene Products><env Polyproteins><env Protein><flexibility><flexible><global health><global health emergency><hCoV19><heavy metal Pb><heavy metal lead><host response><immune serum><immune system response><immunogen><immunogenicity><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><model of animal><model organism><mouse model><murine model><nCoV><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><new CoV><new corona virus><new coronavirus><novel><novel CoV><novel corona virus><novel coronavirus><pandemic><pandemic disease><particle><pathogen><pathogenic virus><promoter><promotor><receptor binding><receptor bound><response><scaffold><scaffolding><severe acute respiratory syndrome-CoV><translation research><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against coronavirus><vaccine candidate><vaccine delivery><vaccine for novel coronavirus><viral pathogen><virtual><virus pathogen>